Dr. Reddy’s Laboratories Launch Sevelamer Carbonate for Oral Suspension in U.S. Market

Dr. Reddy’s Laboratories Ltd. (, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October 2018 according to IMS Health*.

Dr. Reddy’s Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90.

Related Topics and Keywords

Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy